Glucotrack (Nasdaq:GCTK) announced today that it appointed Erin Carter to its board of directors, naming her chair of its audit committee. Carter’s appointment comes just days after the implantable continuous glucose monitor (CGM) maker named Drinda Benjamin VP of marketing. She becomes a member of the board and chair of the audit committee, effective immediately. “We […]
Glucotrack
Implantable CGM maker Glucotrack names new VP of marketing
Glucotrack (Nasdaq:GCTK) announced that it appointed Drinda Benjamin as its new vice president of marketing. Rutherford, New Jersey-based Glucotrack develops an implantable continuous glucose monitor (CGM). It designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. A recent feasibility study demonstrated reliable glucose measurements for two years post-implant for the device. […]
Feasibility study backs Glucotrack implantable CGM
Glucotrack (Nasdaq:GCK) announced today that it completed a feasibility study for its implantable continuous glucose monitor (CGM). Rutherford, New Jersey-based Glucotrack designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. The company said late last year that it planned to expand its product pipeline with an R&D program. The program centers around developing […]
GlucoTrack hires former Dexcom scientist as VP of sensor technology
GlucoTrack (Nasdaq:GCTK) announced today that it appointed Mark Tapsak as its vice president of sensor technology. Tapsak, a veteran of more than 25 years in the diabetes industry, joins the company, effective immediately. His experience includes time spent as a medical device research scientist. He focused on polymer synthesis, polymer characterization, medical device design and […]
GlucoTrack to begin R&D for new long-term CGM
GlucoTrack (Nasdaq:GCTK) announced that it plans to expand its product pipeline with a R&D program for a long-term continuous glucose monitor (CGM). Rutherford, New Jersey-based GlucoTrack said it recently required related IP. It now intends to develop a long-term, implantable glucose management platform for the type 1 diabetes market. Initial data gives the company confidence […]
GlucoTrack provides positive update on next-gen glucose monitor
GlucoTrack (Nasdaq:GCTK) announced today that its second-generation glucose monitor device has shown promising results in analyses. Rutherford, New Jersey-based GlucoTrack — formerly known as Integrity Applications (Nasdaq:IGAP) — earlier this year completed lab testing of the non-invasive GlucoTrack 2.0 clinical prototype system and has observed better-than-expected accuracy and performance with the technology. According to a […]
Integrity Applications changes company name to GlucoTrack
Integrity Applications (Nasdaq:IGAP) announced today that it completed the change of its corporate name to GlucoTrack. Rutherford, New Jersey-based GlucoTrack confirmed the change of its ticker symbol on the Nasdaq capital market to “GCTK,” which was made effective at the commencement of trading today, March 14, 2022. GlucoTrack develops the GlucoTrack non-invasive device and digital […]
Teva Pharma CEO Vigodman steps down | Personnel Moves, February 7, 2017
Teva Pharmaceuticals (NYSE:TEVA) said this week that CEO Erez Vigodman has stepped down from their position at the head of the world’s biggest generic drugmaker. Vigodman’s exit from the company will take effect immediately, with board chair Yitzhak Peterburg taking on the interim role of chief exec. Israel-based Teva has seen shares plummet after a series of […]
